Skip to main content

Table 4 MAb 1G5.3 reactions against DENV glycoprotein, HIV-1 gp41 and mammalian blood-clotting factor IX peptides

From: Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies

Agent/Proteina

Epitope/peptide name/domain (DOM) (Status)b

Peptide sequencec

ELISA Absd

DENV-2/NS1

24C

299-RTTTASGKLIT-309

3.547

DENV-4/NS1

24C

299-RTTTASGKLVT-309

4.324

DENV-2/NS1

24C (303-A/V Sub)

299-RTTTV SGKLIT-309

0.236

DENV-2/NS1

24C (Rev)

309-TILKGSATTTR-299

0.232

DENV-2/NS1

24C (Core sequence)

301-TTASGKLI-308

3.264

DENV-2/NS1

24C (298-C Ins/303-A/C Sub/Red)

C 299-RTTTC SGKLIT-309

1.032

DENV-2/NS1

24C (298-C Ins/303-A/C Sub/Ox Intra)

C 299-RTTTC SGKLIT-309

3.161

DENV-2/NS1

24C (305-G/V Sub)

299-RTTTASV KLIT-309

0.198

DENV-2/NS1

24C (298-C Ins/305-G/C Sub/Ox Intra)

C 299-RTTTASC KLIT-309

0.110

DENV-2/NS1

24C (305-G Del)

299-RTTTASKLIT-309

0.125

DENV-1/NS1

N-TERM (Red)

3-GCVINWKGRELKCG-16

0.064

DENV-2/NS1

N-TERM (Red)

3-GCVVSWKNKELKCG-16

0.111

DENV-3/NS1

N-TERM (Red)

3-GCVINWKGKELKCG-16

0.073

DENV-4/NS1

N-TERM (Red)

3-GCVVSWSGKELKCG-16

3.602

DENV-1-4/E

Dom III

391-WFKKGSSIG-399

0.111

DENV-1-4/E

Dom III (393-KKGSS-397 Inv)

391-WFSSGKK IG-399

0.864

DENV-4/E

Dom II (Red)

116-CAKFSCSGKITK-127

1.323

DENV-4/E

Dom II (Ox Intra)

116-CAKFSCSGKITK-127

1.951

DENV-4/E

Dom II (121-C/G Sub)

116-CAKFSG SGKITK-127

1.221

DENV-4/E

Dom III (309-C Ins/Red)

298-SYTMCSGKFSI-308C

0.122

DENV-4/E

Dom III (309-C Ins/Ox Intra)

298-SYTMCSGKFSI-308C

0.324

DENV-4/E

Dom III (309-C Ins/303-C/G Sub)

298-SYTMG SGKFSI-308C

0.342

Factor IX

Gla Dom (7-γE/E, 8-γE/G Subs)

1-YNSGKLEG FV-10

1.791

Factor IX

Gla Dom (2-N/A,7-γE/E, 8-γE/G Subs)

1-YA SGKLEG FV-10

2.795

HIV-1/gp41

Gnann (Red)

598-LGIWGCSGKLICT-609

2.735

HIV-1/gp41

Gnann (Ox 603-C-608-C Intra)

598-LGIWGCSGKLICT-609

3.673

HIV-1/gp41

Gnann (Red)

598-LGIWGCSGKLICT-609

3.518

HIV-1/gp41

Gnann (Ox 603-C Inter/608-C Inter)

598-LGIWGCSGKLICT-609

3.823

HIV-1/gp41

Gnann (603-C and 608-C/G Subs)

598-LGIWGG SGKLIG T-609

3.642

  1. aInfectious agents as dengue virus type-1 to −4 (DENV-1 to DENV-4) or human immunodeficiency virus-1 (HIV-1) and the protein as the DENV nonstructural-1 (NS1) or envelope (E) glycoprotein, HIV-1 envelope glycoprotein 41 (gp41) or the mammalian blood-clotting factor IX.
  2. bEpitope name (e.g. the 24C or Gnann epitopes) or peptide (e.g. N-TERM) name from the DENV NS1 glycoprotein or the antigenic domain (Dom II or III) of the DENV E glycoproteins or the Gla domain (Gla Dom) of blood-clotting factor IX. The peptide status as being prepared in the reverse orientation (Rev), containing a substitution (Sub) (e.g. 303-A by V substitution = 303-A/V Sub), insertion (Ins) or deletion (Del), or having their cysteine (C) residues reduced (Red) or oxidized (Ox) to form intra-peptide (Intra) or inter-peptide (Inter) cysteine bonds.
  3. cThe amino acid sequence location, with the peptides prepared in the reverse orientation or containing substituted, inserted or inverted amino acid residues (underlined).
  4. dAverage ELISA absorbance (490 nm) against duplicate peptides when reacted at a dilution of 50 times their reciprocal 50% end-point ELISA titer obtained against the native hexameric DENV-2 NS1 glycoprotein (standard deviation range: 0.00 (low values) to 0.09 (high values)). Absorbance values above 1.000 are underlined and those above 3.000 are shown in bold.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us